Loading...
OTCM
HRGN
Market cap25mUSD
Dec 05, Last price  
1.85USD
1D
12.12%
1Q
5.41%
Jan 2017
107.87%
IPO
-98.49%
Name

Biostage Inc

Chart & Performance

D1W1MN
OTCM:HRGN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.08%
Rev. gr., 5y
-18.35%
Revenues
0k
000022,00093,000118,00082,0000000000
Net income
-8m
L-37.27%
-580,000-1,352,000-3,751,000-6,713,000-8,817,000-11,061,000-11,704,000-11,579,000-11,916,000-7,529,000-8,267,000-4,849,000-7,448,000-12,326,000-7,732,000
CFO
-5m
L-30.08%
-480,000-1,048,000-3,573,000-5,897,000-7,686,000-7,993,000-7,186,000-9,058,000-11,014,000-7,638,000-6,059,000-4,041,000-2,628,000-5,106,000-6,939,000-4,852,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
URL
https://www.biostage.com/
IPO date
Oct 14, 2013
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT